A retrospective analysis of ICI induced endocrinopathies at YGC
Research type
Research Study
Full title
A retrospective cohort study of immune checkpoint inhibitor induced endocrinopathies at cancer treatment centre YGC
IRAS ID
360494
Contact name
Qaisar farooq
Contact email
Sponsor organisation
Betsi Cadwaladr Univresity Health Board
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
There has been increasing use of immune checkpoint inhibitors (ICI) to treat various cancers however these have been associated with the development of certain endocrine (hormonal) disorders and inflammation of hormone glands e.g. thyroid, pituitary, adrenal and pancreas. These endocrine side effects can be challenging to treat and can result in discontinuation of the ICI agent, limiting the treatment options available for these patients.
This will be a retrospective cohort study that will investigate all patients treated with ICI at the cancer treatment centre at YGC from Jan 2022 to Feb 2025. Multiple variables (e.g. sex, age, duration of treatment, cancer type, ICI agent, number of cycles etc.) will be assessed to determine if there is any association with the development of hormonal disorders.
This research will use locally collected data already available from the usual care of these patients and data that was already collected for clinical audit purposes. Patients will not be contacted or affected in any way. There will be no changes to the treatment course of the patients during this study.
No funding is being provided. There are no conflicts of interest.
REC name
N/A
REC reference
N/A